All News
WIN-Lupus. RCT of stopping treatment in SLE. All on HCQ. Randomised to stop Aza/MMF after being stable on for 2-3 years. Relapse proliferative nephritis in 25% vs 10%. Severe SLE flare 32% vs 13%. @RheumNow #EULAR2022 OP0280 https://t.co/IAcCoKw1YI
Links:
Richard Conway RichardPAConway ( View Tweet)
It was a pleasure to eat with editors of @RheumJnl at the first evening of #EULAR2022 @LatikaGupta_ @drdj @docrota @SteZhao @ElenaNikiUK
Best Rheumatology journal 🥳🥳 https://t.co/oTDWRUh0Fb
Emre Bilgin, MD dr_emrebilgin ( View Tweet)
So maybe, when it comes to delivering healthcare and telemedicine, we need to think about quality and efficiency? #EULAR2022 @RheumNow https://t.co/JMbQ1ZUB0o
David Liew drdavidliew ( View Tweet)
and, Robert Landewe argues, telemedicine is merely exchanging parcels of information.
Life visits deliver the chance for empathy #EULAR2022 @RheumNow https://t.co/2CKTJHfF7A
David Liew drdavidliew ( View Tweet)
Quality patient communication is actually critical to outcome #EULAR2022 @RheumNow https://t.co/37Z7hwrWmX
David Liew drdavidliew ( View Tweet)
What's the argument against that?
Fundamentally, empathy. The patient experience isn't just a product of miracle drugs - over time it's a multitude of factors that are what leads to happy patients
#EULAR2022 @RheumNow https://t.co/8GwhdT8cit
David Liew drdavidliew ( View Tweet)
and if we don't act, we leave it to the wild, wild west of the private market:
- designed for profit (not necessarily bad)
- but often at the cost of robust dedication to patient outcomes (always bad)
#EULAR2022 @RheumNow https://t.co/zfJWTZ3I1G
David Liew drdavidliew ( View Tweet)
In fact, in some select situations we can get by very well without seeing our patient at all?
#EULAR2022 @RheumNow https://t.co/4qcaj2KR9B
David Liew drdavidliew ( View Tweet)
So maybe telemedicine can bring us the efficiency that we badly need. In rheumatology, we're drowning in demand - is telemedicine part of the solution?
#EULAR2022 @RheumNow https://t.co/kHBIYRIvBA
David Liew drdavidliew ( View Tweet)
✨ Inflammatory #Myositis✨
👉 Excellent summary of Autoantibodies, Immune alterations and Distinct Phenotypes by Dr. Lisa Rider
#EULAR2022 https://t.co/KLzmLUGk9Z
Ashima Makol MD AshimaMakol ( View Tweet)
Watch: New 2022 EULAR RA Treatment Guidelines
https://t.co/mF4cKJLtbr
#EULAR2022 https://t.co/oI8p6gL0Tf
Links:
Dr. John Cush RheumNow ( View Tweet)
Teng et al BLISS-BELIEVE Biomarker outcome RCT Sequential belimumab-rituximab in SLE. Certainly appears to be a serologic benefit on dsDNA, C3/4. But we need clinical parameters to correlate with this. @RheumNow #EULAR2022 OP0281 https://t.co/iEeSN0SNcr https://t.co/HN8ya4QZLU
Links:
Richard Conway RichardPAConway ( View Tweet)
Manzi et al. Data on anifrolumab from TULIP studies on depression/suicidality. No effect. @RheumNow #EULAR2022 OP0282 https://t.co/5n7HBqzLkX https://t.co/fq4dxskJaA
Links:
Richard Conway RichardPAConway ( View Tweet)
Roberto Giacomeilli from Italy explaining the mechanisms on how COVID-19 may cause rheumatic disease #EULAR2022 @RheumNow https://t.co/a2kTT7vcRx
Dr. Antoni Chan synovialjoints ( View Tweet)
Nossent et al Hospitalisation with opportunistic infection twice as high in RA vs AxSpA/PsA. Has IMPROVED over biologic era. To me, suggests benefits of proper disease control on infection risk
@RheumNow
#EULAR2022 OP0274 https://t.co/cqUoRti4We https://t.co/Ozz7jH3z4N
Links:
Richard Conway RichardPAConway ( View Tweet)
Catching up with Jack, a great teacher and educator @RheumNow #rheum #rheumedu #EULAR2022 https://t.co/2wqbhpIb2P
Dr. Antoni Chan synovialjoints ( View Tweet)
LDA/MDA achieved in 60% of PsA pts on (mostly) bDMARDs. Combo baseline features: TJC>3, SJC>5, CRP>10 mg/l, HAQ>0.5, enthesitis, dactylitis, BMI>30  & sDMARDs tx constitutes negative predictive impact on MDA/LDA after 1 yr. #EULAR2022 POS0080 @RheumNow https://t.co/PugwiuSMPm https://t.co/nqadEjA3Xe
Dr. Rachel Tate uptoTate ( View Tweet)
Izokibep - potent and small molecule IL-17A inhibitor Phase 2 study in PsA patients
Fast onset, met ACR50 primary endpoint
AE included site reaction and candida infection
@RheumNow #EULAR2022 ABST#OP0258 https://t.co/vZ4xmnhyhl
Robert B Chao, MD doctorRBC ( View Tweet)
I could listen to Dennis McGonagle talk about enthesitis all day.
If you missed it, one to check out later #EULAR2022 @RheumNow https://t.co/8pRKqMB06j
David Liew drdavidliew ( View Tweet)
Add on MTX does not impair UST immunogenicity in PsA. #EULAR2022 POS0079 @RheumNow
https://t.co/CalEn7KpsX https://t.co/NZUqdX0XKo
Dr. Rachel Tate uptoTate ( View Tweet)